Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
alpha antitrypsin deficiency aatd market size analysis

SALE

Alpha- Antitrypsin Deficiency (AATD) - Market Insight, Epidemiology and Market Forecast - 2030

Published Date : 2020

Pages : 176

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
Companies
- Sample Request

alpha antitrypsin deficiency aatd market size analysis

DelveInsight's "Alpha-Antitrypsin Deficiency - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Alpha-Antitrypsin Deficiency, historical and forecasted epidemiology as well as the Alpha-Antitrypsin Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alpha-Antitrypsin Deficiency market report provides current treatment practices, emerging drugs, Alpha-Antitrypsin Deficiency market share of the individual therapies, current and forecasted Alpha-Antitrypsin Deficiency market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alpha-Antitrypsin Deficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Alpha-Antitrypsin Deficiency Disease Understanding and Treatment Algorithm

Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.

The DelveInsight Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.

Alpha-Antitrypsin Deficiency Epidemiology

The Alpha Antitrypsin Deficiency (AATD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017 - 2030.

According to DelveInsight, the total number of prevalent cases of Alpha Antitrypsin Deficiency (AATD) in 6 MM was found to be 175,009, in the year 2017.

Alpha-Antitrypsin Deficiency Drug Chapters

This segment of the Alpha Antitrypsin Deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current treatment for AATD includes both medicinal and surgical therapies. Both of these categories rely on providing symptomatic relief to the subjects based on the level and severity of their conditions. Commonly used therapy for AATD is similar to chronic obstructive pulmonary disease (COPD) and emphysema treatment: abstinence from smoking, long-acting bronchodilators, antibiotics, inhalations of corticosteroids, and long-acting beta-agonists are recommended.

However, the application of such solutions does not increase the functional AAT level in serum. The only currently approved and dedicated treatment for AATD is Augmentation therapy. Weekly intravenous supplementation with the AAT protein purified from pooled healthy donors' plasma that has become available since the end of the 1980s. It is based on the administration of the purified human AAT at a dose of 60 mg/kg per week in order to achieve the protective level of AAT in serum.

Alpha-Antitrypsin Deficiency Market Outlook

The Alpha Antitrypsin Deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017, and is expected to increase during the course of the study period (2017–2030). Among the 6MM, the United States accounts for the largest market size of AATD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).

Alpha-Antitrypsin Deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Alpha-Antitrypsin Deficiency market or expected to get launched in the market during the study period 2017-2030. The analysis covers Alpha-Antitrypsin Deficiency market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alpha-Antitrypsin Deficiency Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Alpha-Antitrypsin Deficiency key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Alpha-Antitrypsin Deficiency emerging therapies.

Reimbursement Scenario in Alpha-Antitrypsin Deficiency

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Alpha-Antitrypsin Deficiency domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Alpha-Antitrypsin Deficiency market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Alpha-Antitrypsin Deficiency Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of Alpha-Antitrypsin Deficiency, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Alpha-Antitrypsin Deficiency epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Alpha-Antitrypsin Deficiency are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Alpha-Antitrypsin Deficiency market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alpha-Antitrypsin Deficiency market

Report Highlights

In the coming years, Alpha-Antitrypsin Deficiency market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Antitrypsin Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Alpha-Antitrypsin Deficiency. Launch of emerging therapies will significantly impact the Alpha-Antitrypsin Deficiency market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Alpha-Antitrypsin Deficiency
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Alpha-Antitrypsin Deficiency Report Insights

Patient Population
Therapeutic Approaches
Alpha-Antitrypsin Deficiency Pipeline Analysis
Alpha-Antitrypsin Deficiency Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Alpha-Antitrypsin Deficiency Report Key Strengths

11 Years Forecast
7MM Coverage
Alpha-Antitrypsin Deficiency Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Alpha-Antitrypsin Deficiency Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions

Market Insights:

What was the Alpha-Antitrypsin Deficiency market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Alpha-Antitrypsin Deficiency total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Alpha-Antitrypsin Deficiency market size during the forecast period (2017-2030)?
At what CAGR, the Alpha-Antitrypsin Deficiency market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Alpha-Antitrypsin Deficiency market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Alpha-Antitrypsin Deficiency market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Alpha-Antitrypsin Deficiency?
What is the historical Alpha-Antitrypsin Deficiency patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Alpha-Antitrypsin Deficiency in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alpha-Antitrypsin Deficiency?
Out of all 7MM countries, which country would have the highest prevalent population of Alpha-Antitrypsin Deficiency during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Alpha-Antitrypsin Deficiency treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Alpha-Antitrypsin Deficiency in the USA, Europe, and Japan?
What are the Alpha-Antitrypsin Deficiency marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Alpha-Antitrypsin Deficiency?
How many therapies are developed by each company for Alpha-Antitrypsin Deficiency treatment?
How many are emerging therapies in mid-stage, and late stage of development for Alpha-Antitrypsin Deficiency treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Alpha-Antitrypsin Deficiency therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Alpha-Antitrypsin Deficiency and their status?
What are the key designations that have been granted for the emerging therapies for Alpha-Antitrypsin Deficiency?
What are the global historical and forecasted market of Alpha-Antitrypsin Deficiency?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Alpha-Antitrypsin Deficiency market
To understand the future market competition in the Alpha-Antitrypsin Deficiency market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Alpha-Antitrypsin Deficiency in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Alpha-Antitrypsin Deficiency market
To understand the future market competition in the Alpha-Antitrypsin Deficiency market

What is Alpha Antitrypsin Deficiency?

Alpha Antitrypsin Deficiency occurs when the body is unable to produce sufficient amounts of Alpha Antitrypsin protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. Alpha Antitrypsin protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.

How is epidemiology segmented for Alpha Antitrypsin Deficiency?

The total prevalent population of Alpha Antitrypsin Deficiency, total diagnosed population of Alpha Antitrypsin Deficiency, genotype of Alpha Antitrypsin Deficiency diagnosed pool and comorbidities associated with Alpha Antitrypsin Deficiency.

What was the Alpha Antitrypsin Deficiency total prevalent cases in 2017?

The total number of prevalent cases of Alpha Antitrypsin Deficiency in 6 MM was found to be 175,009 in the year 2016.

What was the Alpha Antitrypsin Deficiency market in 2017?

The market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017.

Which companies are developing drugs for Alpha Antitrypsin Deficiency?

Kamada Ltd, Alnylam Pharmaceuticals, Arrow Head Pharmaceuticals, Vertex Pharmaceuticals, Mereo Biopharma, Dicerna Pharmaceuticals are developing drugs for Alpha Antitrypsin Deficiency.

1. Key Insights

2. Executive Summary of Alpha Antitrypsin Deficiency

3. SWOT Analysis for Alpha Antitrypsin Deficiency

4. Patient Share of Alpha Antitrypsin Deficiency at a Glance

4.1. Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017

4.2. Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030

5. Alpha Antitrypsin Deficiency Market Overview at a Glance

5.1. Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2017

5.2. Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2030

6. Disease Background and Overview

6.1. Introduction

6.2. Symptoms

6.3. Etiology

6.4. Risk Factors

6.5. Genetic Inheritance of AAT Deficiency

6.6. Clinical Manifestations

6.7. Pathophysiology

6.8. Biomarkers

6.9. Diagnosis

6.10. Diagnostic Delay

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM

8. Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency

8.1. Assumptions and Rationale: 6MM

8.2. United States

8.2.1. Prevalence of Symptomatic AATD in the United States

8.2.2. Diagnosed population of AATD in the United States

8.2.3. Genotype of AATD Diagnosed patients in the United States

8.2.4. Comorbidity associated with AATD in the United States

8.3. EU5

8.3.1. Germany

8.3.1.1. Prevalence of Symptomatic AATD in Germany

8.3.1.2. Diagnosed population of AATD in Germany

8.3.1.3. Genotype of AATD Diagnosed patients in Germany

8.3.1.4. Comorbidity associated with AATD in Germany

8.3.2. France

8.3.2.1. Prevalence of Symptomatic AATD in France

8.3.2.2. Diagnosed population of AATD in France

8.3.2.3. Genotype of AATD Diagnosed patients in France

8.3.2.4. Comorbidity associated with AATD in France

8.3.3. Italy

8.3.3.1. Prevalence of Symptomatic AATD in Italy

8.3.3.2. Diagnosed population of AATD in Italy

8.3.3.3. Genotype of AATD Diagnosed patients in Italy

8.3.3.4. Comorbidity associated with AATD in Italy

8.3.4. Spain

8.3.4.1. Prevalence of Symptomatic AATD in Spain

8.3.4.2. Diagnosed population of AATD in Spain

8.3.4.3. Genotype of AATD Diagnosed patients in Spain

8.3.4.4. Comorbidity associated with AATD in Spain

8.3.5. United Kingdom

8.3.5.1. Prevalence of Symptomatic AATD in the United Kingdom

8.3.5.2. Diagnosed population of AATD in the United Kingdom

8.3.5.3. Genotype of AATD Diagnosed patients in the United Kingdom

8.3.5.4. Comorbidity associated with AATD in the United Kingdom

9. Treatment

9.1. Current therapies

9.1.1. Augmentation Therapy

9.1.2. Gene Therapy strategies

9.1.3. Lifestyle Changes

9.1.4. Novel therapeutics

10. Treatment Algorithm

10.1. Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease

10.2. Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

11. Unmet Needs

12. Organizations contributing toward Alpha Antitrypsin Deficiency

13. Case Reports

13.1. An unusual case of alpha-1-antitrypsin deficiency: SZ/Z

13.2. The Importance of Early Identification of Alpha-1 Antitrypsin Deficiency

13.3. A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis

14. Marketed Drugs

14.1. Prolastin C: Grifols

14.1.1. Drug Description

14.1.2. Mechanism of Action

14.1.3. Regulatory Milestones

14.1.4. Advantages and Disadvantages

14.1.5. Safety and Efficacy of Prolastin-C

14.2. Glassia: Kamada

14.2.1. Drug Description

14.2.2. Mechanism of Action

14.2.3. Regulatory Milestones

14.2.4. Advantages and Disadvantages

14.2.5. Safety and Efficacy of Glassia

14.3. Aralast: Shire

14.3.1. Drug Description

14.3.2. Mechanism of Action

14.3.3. Regulatory Milestones

14.3.4. Advantages and Disadvantages

14.3.5. Safety and Efficacy of Aralast

14.4. Zemaira: CSL Behring

14.4.1. Drug Description

14.4.2. Mechanism of Action

14.4.3. Regulatory Milestones

14.4.4. Advantages and Disadvantages

14.4.5. Safety and Efficacy of Zemaira

14.5. Alfalastin: LFB Biotechnologies

14.5.1. Description

14.5.2. Regulatory Milestones

14.5.3. Advantages and Disadvantages

14.5.4. Safety and Efficacy

14.6. Trypsone: Grifols

14.6.1. Description

14.6.2. Regulatory Milestones

14.6.3. Advantages and Disadvantages

14.6.4. Efficacy and Safety

15. Emerging Therapies

15.1. Inhaled AAT (Glassia IH): Kamada Ltd

15.1.1. Product Description

15.1.2. Regulatory Milestones

15.1.3. Product Development Activities

15.1.4. Clinical Development

15.1.4.1. Clinical Trials Information

15.1.5. Safety and Efficacy

15.2. ALN-AAT02: Alnylam Pharmaceuticals

15.2.1. Product Description

15.2.2. Product Development Activities

15.2.3. Clinical development

15.2.3.1. Clinical Trials Information

15.2.4. Safety and Efficacy

15.3. ARO-AAT: Arrow Head Pharmaceuticals

15.3.1. Product Description

15.3.2. Product Development Activities

15.3.3. Clinical Development

15.3.3.1. Clinical Trials Information

15.3.4. Safety and Efficacy

15.4. VX-814: Vertex Pharmaceuticals

15.4.1. Product Description

15.4.2. Product Development Activities

15.4.3. Clinical Development

15.4.3.1. Clinical Trials Information

15.5. Alvelestat (MPH-966): Mereo Biopharma

15.5.1. Product Description

15.5.2. Product Development Activities

15.5.3. Clinical Development

15.5.3.1. Clinical Trials Information

15.6. DCR-A1AT: Dicerna Pharmaceuticals

15.6.1. Product Description

15.6.2. Product Development Activities

15.6.3. Clinical Development

15.6.3.1. Clinical Trial Information

15.6.4. Pre-clinical Results

16. Other Promising Candidates

16.1. INBRX-101: Inhibrx

16.1.1. Product Description

16.1.2. Product Development Activities

16.1.3. Clinical development

16.2. Carbamazepine: Novartis Pharmaceuticals

16.2.1. Product Description

16.2.2. Clinical Development

16.2.2.1. Clinical Trials Information

16.3. VX-864: Vertex Pharmaceuticals

16.3.1. Product Description

17. Alpha Antitrypsin Deficiency: 6 Major Market Analysis

17.1. Total Market Size of AATD

18. Alpha Antitrypsin Deficiency: Country-Wise Market Analysis

18.1. United States

18.1.1. Total Market Size of AATD

18.1.2. Market Size of Alpha Antitrypsin Deficiency by Therapies in United States

18.2. EU-5

18.2.1. Germany

18.2.1.1. Total Market Size of AATD in Germany

18.2.1.2. Market Size of Alpha Antitrypsin Deficiency by Therapies in Germany

18.2.2. France

18.2.2.1. Total Market Size of AATD in France

18.2.2.2. Market Size of Alpha Antitrypsin Deficiency by Products in France

18.2.3. Italy

18.2.3.1. Total Market Size of AATD in Italy

18.2.3.2. Market Size of Alpha Antitrypsin Deficiency by Products in Italy

18.2.4. Spain

18.2.4.1. Total Market Size of AATD in Spain

18.2.4.2. Market Size of Alpha Antitrypsin Deficiency by Products in Spain

18.2.5. United Kingdom

18.2.5.1. Total Market Size of AATD in The UK

18.2.5.2. Market Size of Alpha Antitrypsin Deficiency by Products in UK

19. Grifols Initiatives towards Alpha Antitrypsin deficiency

20. US FDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

21. Market Drivers

22. Market Barriers

23. Access and Reimbursement Overview of Alpha Antitrypsin Deficiency

23.1. The Italian Experience

23.2. Augmentation Therapy - slowly finding its way in the UK

23.3. The Changing Future

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Tables:

List of Tables:

Table 1: Summary of Alpha-1 Antitrypsin Deficiency (AATD) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Diagnostic Delay Interval for AATD

Table 3: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2017–2030)

Table 4: Prevalence of Symptomatic AATD in the United States (2017–2030)

Table 5: Diagnosed population of AATD in the United States (2017–2030)

Table 6: Genotype of AATD Diagnosed patients in the United States (2017–2030)

Table 7: Comorbidity associated with AATD in the United States (2017–2030)

Table 8: Prevalence of Symptomatic AATD in Germany (2017–2030)

Table 9: Diagnosed population of AATD in Germany (2017–2030)

Table 10: Genotype of AATD Diagnosed patients in Germany (2017–2030)

Table 11: Comorbidity associated with AATD in Germany (2017–2030)

Table 12: Prevalence of Symptomatic AATD in France (2017–2030)

Table 13: Diagnosed population of AATD in France (2017–2030)

Table 14: Genotype of AATD Diagnosed patients in France (2017–2030)

Table 15: Comorbidity associated with AATD in France (2017–2030)

Table 16: Prevalence of Symptomatic AATD in Italy (2017–2030)

Table 17: Diagnosed population of AATD in Italy (2017–2030)

Table 18: Genotype of AATD Diagnosed patients in Italy (2017–2030)

Table 19: Comorbidity associated with AATD in Italy (2017–2030)

Table 20: Prevalence of Symptomatic AATD in Spain (2017–2030)

Table 21: Diagnosed population of AATD in Spain (2017–2030)

Table 22: Genotype of AATD Diagnosed patients in Spain (2017–2030)

Table 23: Comorbidity associated with AATD in Spain (2017–2030)

Table 24: Prevalence of Symptomatic AATD in The United Kingdom (2017–2030)

Table 25: Diagnosed population of AATD in The United Kingdom (2017–2030)

Table 26: Genotype of AATD Diagnosed patients in The United Kingdom (2017–2030)

Table 27: Comorbidity associated with AATD in The United Kingdom (2017–2030)

Table 28: Organizations contributing toward Alpha-Antitrypsin Deficiency

Table 29: Inhaled AAT, Clinical Trial Description, 2020

Table 30: ALN-AAT02, Clinical Trial Description, 2020

Table 31: ARO-AAT, Clinical Trial Description, 2020

Table 32: VX-814, Clinical Trial Description, 2020

Table 33: Alvelestat, Clinical Trial Description, 2020

Table 34: DCR-A1AT, Clinical Trial Description, 2020

Table 35: INBRX-101, Clinical Trial Description, 2020

Table 36: Carbamazepine, Clinical Trial Description, 2020

Table 37: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017–2030)

Table 38: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017–2030)

Table 39: US Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)

Table 40: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)

Table 41: Germany Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)

Table 42: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)

Table 43: France Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)

Table 44: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)

Table 45: Italy Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)

Table 46: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)

Table 47: Spain Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)

Table 48: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)

Table 49: UK Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)

List of Figures:

List of Figures

Figure 1: Swot Analysis

Figure 2: Historical Overview Of AATD Development

Figure 3: Symptoms Associated With Alpha Antitrypsin Deficiency

Figure 4: Risk Factors For AATD

Figure 5: Inheritance Of AATD

Figure 6: Inheritance Pattern Of AATD

Figure 7: Alpha-1 Antitrypsin Binds And Inactivates Neutrophil Elastase.

Figure 8: Pathogenesis Of Alpha Antitrypsin Deficiency

Figure 9: Diagnostic Algorithm Of Alpha Antitrypsin Deficiency

Figure 10: Ats/Ers Diagnostic Recommendations For Alpha Antitrypsin Deficiency

Figure 11: Ats/Ers Recommendations (To Be Discussed) For Alpha Antitrypsin Deficiency

Figure 12: Ats/Ers Diagnostic Recommendations (Not Recommended) For Alpha Antitrypsin Deficiency

Figure 13: Diagnostic And Monitoring Methods For Alpha Antitrypsin Deficiency

Figure 14: Total Prevalent Population Of Alpha-1-Antitrypsin Deficiency In 6 Mm (2017–2030)

Figure 15: Prevalence Of Symptomatic AATD In The United States (2017–2030)

Figure 16: Diagnosed Population Of AATD In The United States (2017–2030)

Figure 17: Genotype Of AATD Diagnosed Patients In The United States (2017–2030)

Figure 18: Comorbidity Associated With AATD In The United States (2017–2030)

Figure 19: Prevalence Of Symptomatic AATD In Germany (2017–2030)

Figure 20: Diagnosed Population Of AATD In Germany (2017–2030)

Figure 21: Genotype Of AATD Diagnosed Patients In Germany (2017–2030)

Figure 22: Comorbidity Associated With AATD In Germany (2017–2030)

Figure 23: Prevalence Of Symptomatic AATD In France (2017–2030)

Figure 24: Diagnosed Population Of AATD In France (2017–2030)

Figure 25: Genotype Of AATD Diagnosed Patients In France (2017–2030)

Figure 26: Comorbidity Associated With AATD In France (2017–2030)

Figure 27: Prevalence Of Symptomatic AATD In Italy (2017–2030)

Figure 28: Diagnosed Population Of AATD In Italy (2017–2030)

Figure 29: Genotype Of AATD Diagnosed Patients In Italy (2017–2030)

Figure 30: Comorbidity Associated With AATD In Italy (2017–2030)

Figure 31: Prevalence Of Symptomatic AATD In Spain (2017–2030)

Figure 32: Diagnosed Population Of AATD In Spain (2017–2030)

Figure 33: Genotype Of AATD Diagnosed Patients In Spain (2017–2030)

Figure 34: Comorbidity Associated With AATD In Spain (2017–2030)

Figure 35: Prevalence Of Symptomatic AATD In The United Kingdom (2017–2030)

Figure 36: Diagnosed Population Of AATD In The United Kingdom (2017–2030)

Figure 37: Genotype Of AATD Diagnosed Patients In The United Kingdom (2017–2030)

Figure 38: Comorbidity Associated With AATD In The United Kingdom (2017–2030)

Figure 39: Treatment Recommendations For AATD

Figure 40: Available Therapeutics Of Alpha Antitrypsin Deficiency

Figure 41: Strategies For Delivery Of Engineered Nucleases: A) Ex-Vivo ; B) In Vivo

Figure 42:Genome Editing With Engineered Nucleases

Figure 43: Treatment Algorithm Of Alpha Antitrypsin Deficiency

Figure 44: Algorithm For Management Of Alpha Antitrypsin Deficiency With Lung Disease

Figure 45: Algorithm For Management Of Alpha Antitrypsin Deficiency With Lung Disease

Figure 46: Current Unmet Needs

Figure 47: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017–2030)

Figure 48: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017–2030)

Figure 49: Us Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017 -2030)

Figure 50: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017-2030)

Figure 51: Germany Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017-2030)

Figure 52: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017-2030)

Figure 53: France Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017-2030)

Figure 54: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017 -2030)

Figure 55: Italy Market Size Of Alpha Antitrypsin Deficiency By Products In USD, Million (2017-2030)

Figure 56: Total Market Size Of Alpha Antitrypsin Deficiency In USD, Million (2017 -2030)

Tags:

License Type

Offer